Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1177MR)

This product GTTS-WQ1177MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1177MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7099MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ241MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ5061MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ4502MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ4534MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ3008MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ242MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ9014MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW